6/11/2019

Change in Orion Corporation's holding of treasury shares

ORION CORPORATION STOCK EXCHANGE RELEASE 11 JUNE 2019 at 11.45 EEST             
         
Change in Orion Corporation's holding of treasury shares

A total of 238 Orion class B shares have been returned free of consideration to Orion Corporation by virtue of the terms of the Company's share-based incentive plan of the year 2016.

After the transfer, Orion Corporation holds 765,399 of its own class B shares.

Orion Corporation

Timo Lappalainen
President and CEO
  Olli Huotari
SVP, Corporate Functions
 

                                                                                                                                   
Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 010 426 3054 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.